1. MMV: Medicines for Treating, Preventing & Eradicating Malaria Penny Grewal Daumerie Director, Global Access, MMV

2. MMV at a Glance  Public-Private Partnership  Established in 1999 by WHO/TDR and the Pharma Industry  Mandate: Discover, develop and deliver safe, effective and affordable antimalarials to treat and protect people most at risk of malaria  Diversified funding base  Swiss Foundation based in Geneva

3. MMV works with partners in 33 countries 3 countries 19 partners 6 countries 20 partners 14 countries 27 partners 10 countries 21 partners Over 80 academic, industry and endemic country partners More than 600 scientists, clinicians, public health experts

4. Global Malaria Portfolio- Q3 2008 MMV is the main driver for antimalarial R&D (50 projects) RegistrationLead OptPhase IIPhase IIIPreclinicalPhase IDiscovery ResearchTranslationalDevelopment Coartem®-D Eurartesim™ Pyramax® Isoquine Ozonides MK 4815 Pyridone 932121 Novartis 9 projects GSK 3 projects Others 6 projects Blue AQ Others 53 projects SAR116242 Trioxanes Artesunate Ferroquine Fosmidomycin Azithromycin Others 1 project Azithromycin chloroquine Amodiaquine Artesunate Mefloquine Artesunate DHODH DHFR NITD Immucillins Einstein Macrolides GSK Pyridones GSK DHFR Thailand Nat Product NITD 5 projects Broad/Genzyme Launch 2014 2012 2010 2008 Arterolane PQP Artemifone SAR97276 Choline Non-MMV projects AQ13 Immtech Tafenoquine IV artesunate